TY - JOUR
AU - Kurzrock, Razelle
AB - INTRODUCTIONAdvances in clinical next generation sequencing (NGS) and the advent of genomically targeted therapies and agents that arm the immune system have altered the landscape of multiple tumor treatments.1 Increased availability of clinical NGS testing, both somatic and germline, has unleashed the era of tumor‐agnostic precision medicine.2–4 In this era, we are witnessing unparalleled advances in our ability to interrogate cancer cells, decipher cancer pathways, and discover drugs to target the gene‐based and immune‐based pathways that drive and permit cancer growth.Clinical trials are the backbone of cancer research, and they advance new agents, new combinations, and new paradigms for treatment to the clinic. Conducting clinical trials efficiently is crucial because they allow us to rigorously evaluate the safety and efficacy of new interventions, paving the way for innovative treatments to reach patients sooner.5,6 Drug development is expensive and time consuming.5 With improved clinical trial designs, we can accelerate the timeline for bringing promising therapies to give our patients faster access to the best possible care.7,8 Efficient design and conduct of clinical trials hold immense promise for expediting access to life‐saving treatments for our patients battling cancer. As clinical trialists in oncology, we cannot emphasize enough the significance of streamlined 
TI - Revolutionizing cancer drug development: Harnessing the potential of basket trials
JO - Cancer
DO - 10.1002/cncr.35085
DA - 2024-01-01
UR - https://www.deepdyve.com/lp/wiley/revolutionizing-cancer-drug-development-harnessing-the-potential-of-gpxo86N0a1
SP - 186
EP - 200
VL - 130
IS - 2
DP - DeepDyve
ER -